Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Emin Oroudjev, Manu Lopus, Leslie Wilson, Charlene Audette, Carmela Provenzano, Hans Erickson, Yelena Kovtun, Ravi Chari, and Mary Ann Jordan

Abstract

Maytansine and its analogues (maytansinoids) are potent microtubule-targeted compounds that inhibit proliferation of cells at mitosis. Antibody-maytansinoid conjugates consisting of maytansinoids (DM1 and DM4) attached to tumor-specific antibodies have shown promising clinical results. To determine the mechanism by which the antibody-DM1 conjugates inhibit cell proliferation, we examined the effects of the cleavable anti-EpCAM-SPP-DM1 and uncleavable anti-EpCAM-SMCC-DM1 conjugates on MCF7 human breast tumor cells. We also examined the effects of the free maytansinoids, maytansine and S-methyl DM1 (a version of DM1 that is stable in cell culture medium), for comparison. Both the conjugates and free maytansinoids potently inhibited MCF7 cell proliferation at nanomolar and subnanomolar concentrations, respectively, by arresting the cells in mitotic prometaphase/metaphase. Arrest occurred in concert with the internalization and intracellular processing of both conjugates under conditions that induced abnormal spindle organization and suppressed microtubule dynamic instability. Microtubule depolymerization occurred only at significantly higher drug concentrations. The results indicate that free maytansinoids, antibody-maytansinoid conjugates, and their metabolites exert their potent antimitotic effects through a common mechanism involving suppression of microtubule dynamic instability.

Introduction

Maytansine and its analogues (Fig. 1) are benzoansamacrolides (1–3) that show powerful antimitotic activity (4, 5). Maytansine (Fig. 1) is a microtubule-targeted drug that binds to tubulin at the Vinca binding site (6, 7). Similar to Vinca alkaloids, maytansine can depolymerize microtubules and arrest cells in mitosis (8–10). However, maytansine displays almost 100 times higher cytotoxicity in cells than the Vinca alkaloids (11).

In human clinical trials, maytansine showed a small therapeutic window due to neurotoxicity and to adverse effects on the gastrointestinal tract (11). However, the powerful cytotoxicity of maytansinoids could make them valuable for anticancer therapies using tissue-specific drug delivery approaches, particularly as antibody-maytansinoid conjugates (AMC; refs. 12–16). Preclinical studies indicate that AMCs have significantly improved potential as anticancer agents compared with the unconjugated maytansinoids (17–19). Clinical trials using several different AMCs have been conducted (20–22). A recent trial on trastuzumab-DM1 (T-DM1), a maytansinoid conjugated to the anti-human epidermal growth factor receptor 2 therapeutic antibody trastuzumab, showed good efficacy in metastatic breast cancer (23). Moreover, the CD56-targeting AMC, lorvotuzumab-mertansine, has shown promising results in solid and liquid tumors that express CD56 (24). T-DM1 (trastuzumab-MCC-DM1) utilizes a nonreducible thioether-based linker, whereas lorvotuzumab mertansine (huN901-SPP-DM1) utilizes a disulfide-based linker (Fig. 1).

The optimal linker for an AMC is selected by preparing conjugates with a panel of linkers and evaluating their activity in vitro and in human tumor xenograft models. The conjugate with the most antitumor activity and the widest therapeutic window, as defined by the difference between the maximum tolerated dose and minimally effective dose, is then selected. Preclinical studies (25, 26) with anti-CanAg (tumor-associated protein CA242)–targeting AMCs showed that the huC242 antibody component of cleavable disulfide-linked huC242-SPP-DM1 and the uncleavable huC242-SMCC-DM1 conjugate is proteolytically degraded in targeted cancer cells following antigen-mediated internalization and vesicular trafficking to the lysosomes to yield lysine-SPP-DM1 and lysine-SMCC-DM1 metabolites, respectively. The lysine-SPP-DM1 derived from the disulfide-linked conjugate

Authors’ Affiliations:

Department of Molecular, Cellular, and Developmental Biology, and the Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, and ImmunoGen, Inc., Waltham, Massachusetts

Corresponding Author: Mary Ann Jordan, Department of Molecular, Cellular, and Developmental Biology, and the Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9610. Phone: 805-893-5317; Fax: 805-893-4724. E-mail: jordan@lifesci.ucsb.edu

doi: 10.1158/1535-7163.MCT-10-0645

©2010 American Association for Cancer Research.
undergoes further intracellular reduction to yield DM1 (25, 26). Formation of the hydrophobic DM1 metabolite is proposed to explain the bystander cell killing activity of huC242-SPP-DM1 that was observed in human tumor xenograft models (19). Microtubules are polymers composed of the protein tubulin that play a major role in mitosis and other important cell functions (27).

Microtubules are highly dynamic polymers, and their dynamics are tightly controlled both spatially and temporally in cells. In one type of dynamics, dynamic instability, the ends of the microtubules alternate between phases of growth and shortening. Recent research shows that many microtubule-targeted compounds, including the Vinca alkaloids, suppress dynamic instability, and they do so at concentrations significantly lower than those required to depolymerize microtubules. Suppression of dynamic instability plays a major role in the antimitotic effects of these drugs (27–29).

In an accompanying article, we report that maytansine and S-methyl DM1 (DM1-Me) bind to soluble tubulin with similar affinities (K_D values of 0.86 and 0.93 μmol/L, respectively), and that they inhibit microtubule polymerization with similar potencies (IC_50 values of 1 and 4 μmol/L, respectively). Using purified bovine brain microtubules in vitro, we found that at a concentration of 100 nmol/L, the maytansinoids suppress dynamic instability by binding with high affinity to a small number of sites at microtubule ends (30). For example, we found that S-methyl DM1 binds to 37 saturable sites on microtubules with a K_D of 0.1 ± 0.05 μmol/L and to a large number of low-affinity sites on microtubules and sedimentable aggregates with a K_D of 2.2 ± 0.2 μmol/L. Thus, their affinity for tubulin at microtubule ends is 20-fold stronger than their affinity for free tubulin.

To understand the mechanism of action of the antibody-conjugated maytansinoids, we investigated the concentration- and time-dependent effects of maytansine, S-methyl DM1, and anti–EpCAM-DM1 conjugates on proliferation, G2-M arrest, microtubule organization, and dynamic instability in MCF7 cells. Although antibody-DM1 conjugates were prepared with the thiol-containing maytansinoid DM1, we found that DM1 can oxidize in aqueous solution to produce a DM1 disulfide dimer or undergo disulfide exchange with cysteine in cell culture medium to give a mixed disulfide. Thus, we used the stable DM1 methyl thioether derivative (S-methyl DM1) in these studies. We found that the antibody-DM1 conjugates, maytansine, S-methyl DM1, and the intracellular metabolites of the antibody-DM1 conjugates all inhibit proliferation and induce mitotic arrest in association with suppression of microtubule dynamic instability.

Materials and Methods

Materials

All chemicals and materials were purchased from Sigma unless otherwise noted. Ultima Gold scintillation fluid was from Perkin-Elmer Life and Analytical Sciences. The high performance liquid chromatography (HPLC) 10 μm C-18 column (0.46 × 25 cm, Vydac) was obtained from the Nest Group. Maytansine was prepared as described previously (17, 31) and stored as aliquots of...
1 mmol/L stock solutions in DMSO at –70°C. DM1 and tritium-labeled DM1 were prepared from ansamitocin P-3 and [3H]ansamitocin P-3, respectively (26). S-[3H]methyl-DM1 was prepared at American Radiocchemicals by reacting DM1 with [3H]methyl iodide. Stock solutions were diluted in DMSO to 1 μmol/L and further diluted in cell culture medium or buffer to the desired concentration, with no more than 1:10 dilution at each step. Antibody-DM1 and antibody-[3H]DM1 conjugates were prepared as described elsewhere (32). The chimeric anti-EpCAM monoclonal antibody B38.1 and the non targeting anti-CD56 antibody were produced at ImmunoGen. Conjugates are described by including the abbreviation for the linkers used in conjugation. The ratio of DM1 molecules linked per antibody molecule was determined as previously described (32) and ranged from 3.5 to 4. AMC concentrations are expressed as the concentration of antibody rather than of the conjugated maytansinoid.

**Cell culture**

MCF7 human breast carcinoma cells stably expressing enhanced green fluorescent protein (EGFP)-α-tubulin (33) were used for all experiments and are referred to as MCF7 cells. The EGFP-α-tubulin–expressing cells were morphologically indistinguishable from unmodified MCF7 (acquired from the American Type Culture Collection), but the doubling time was increased by 20%. They were free of Mycoplasma as determined by Hoechst 33342 stain (Life Technologies) and MycoAlert Mycoplasma detection kit (Lonza). The expression level of EpCAM was identical on both unmodified MCF7 and EGFP-α-tubulin–expressing MCF7 cells (as verified by binding of muB38.1 antibody).

MCF7 cells were cultured as adherent cells in high glucose (4 g/L) and 25 mmol/L HEPES-fortified DMEM supplemented with 1× nonessential amino acids and 10% fetal bovine serum (Hyclone), and 0.5 mg/mL G418 (Biowhit) supplemented with 1× nonessential amino acids and 10% fetal bovine serum (4 g/L) and 25 mmol/L HEPES-fortified DMEM supplemented with no more than 1:10 dilution at each step. Antibody-DM1 and antibody-[3H]DM1 conjugates were prepared as described elsewhere (32). The chimeric anti-EpCAM monoclonal antibody B38.1 and the non targeting anti-CD56 antibody were produced at ImmunoGen. Conjugates are described by including the abbreviation for the linkers used in conjugation. The ratio of DM1 molecules linked per antibody molecule was determined as previously described (32) and ranged from 3.5 to 4. AMC concentrations are expressed as the concentration of antibody rather than of the conjugated maytansinoid.

**Cell proliferation**

Proliferation was measured by a modified sulforhodamine B assay (34). MCF7 cells were seeded at 2 × 10⁴ per well in 96-well plates and incubated for 24 hours to allow cell attachment and recovery. Medium with or without maytansinoid was then added for a 72-hour incubation. Cells were fixed, stained, and the optical density (OD) of each well was determined (490 nm; Victor3V Wallac 1420 Spectrophotometer, Perkin-Elmer). The percentage of inhibition of cell proliferation was calculated as follows: 100 – [OD sample at 72 hours – OD control at 0 hour]/(OD control at 72 hours – OD control at 0 hour]. The 50% proliferation inhibitory concentrations (anti proliferative IC₅₀) were calculated by fitting the concentration–response data with a sigmoid function using IGOR Pro 6.0 software (WaveMetrics). Triplicates of each condition were tested in each experiment. Results are mean and SEM of at least three independent experiments.

**Cell cycle and mitotic index**

MCF7 cells were seeded at 6 × 10⁴ per 2 mL into six-well plates. After a 24-hour recovery period, fetal bovine serum (FBS) was reduced to 2% for another 24 hours (to duplicate the conditions used for imaging dynamic microtubules), then cells were incubated for 24 hours in culture medium with 10% FBS + maytansinoid. Floating and adherent cells were collected, combined, concentrated by centrifugation, fixed, permeabilized with ice-cold 70% ethanol, washed with PBS, and stained with a Guava Cell Cycle Reagent (Guava Technologies) according to the manufacturer's protocol. The DNA content of ≥3,000 cells was measured by flow cytometry on Guava EasyCyte for each condition. Cell cycle distribution was analyzed by ModFit software (Verity Software House). Results are the mean and SEM of at least three independent experiments.

MCF7 cells were grown attached to coverslips pretreated with poly-L-lysine (400 μg/mL) or in six-well tissue culture plates and incubated with compound as in the cell cycle experiments. Cells (either on coverslips or detached from six-well plates by trypsinization) were fixed with 3.7% formaldehyde, stained with Alexa Fluor 488–conjugated anti-phosphohistone H3 antibody (Cell Signaling Technology), and imaged by immunofluorescence microscopy as described below. The proportion of cells that were positive for phosphorylated H3 histone (a mitotic marker) was measured by flow cytometry on Guava EasyCyte (Guava Technologies) or by microscopy on the Nikon Eclipse E800 (Nikon) microscope. The half-maximal mitotic arrest concentrations (IC₅₀) were calculated as described above.

**Immunofluorescence microscopy**

Cells were seeded on coverslips as above, incubated with maytansinoid for 24 hours, and fixed with 3.7% formaldehyde. Microtubules were stained with mouse monoclonal α-tubulin antibody (DM1A, Sigma-Aldrich) and FITC-conjugated goat anti-mouse antibody (Cappell MP Bio chemicals). Centrosomes were stained with rabbit polyclonal anti-pericentrin antibody (AB4448, Abcam) and rhodamine-conjugated goat anti-rabbit antibody (Cappell MP Biochemicals). Actin filaments were stained with rhodamine-conjugated phalloidin (Invitrogen). Cells were mounted with 4′,6-diamidino-2-phenylindole–containing Prolong Gold (Invitrogen). Microscopy was done on a spinning disc confocal microscope Olympus IX81 DSU (Olympus). Images were taken by ImagEM camera (Hamamatsu) under the control of the SlideBook software (Olympus).

**Uptake of S-[3H]methyl-DM1 by MCF-7 cells**

To measure uptake of S-methyl DM1, MCF7 cells (2 × 10⁴/mL) were incubated with 780 pmol/L S-[3H]methyl-DM1 (specific activity ~500 mCi/mmol), at 37°C for 7 hours. At each 1-hour time point, 1 mL of sample was harvested, cells were separated from the supernatant by centrifugation, and the supernatant was transferred to a 1 mL Eppendorf tube. Each cell pellet was washed with
10 mL culture medium. Cells were pelleted by centrifugation and lysed with 400 μL of lysis buffer [50 mmol/L Tris (pH 8.0), 200 mmol/L NaCl, 15 mmol/L EDTA, and 1% v/v Triton X-100]. Radioactivity in lysed cell pellets and supernatants were counted using a Packard Tri-Carb 2900 TR liquid scintillation analyzer.

Extraction of [3H]maytansinoid metabolites following exposure of MCF-7/GFP cells to B38.1-[3H]DM1 conjugates in vitro

 Cultures of MCF-7/GFP cells (9 × 10^6) were exposed to 10 nmol/L Ab-[3H]DM1 conjugates and incubated at 37°C for 5, 9, or 24 hours. The cells were harvested with trypsin, washed with PBS, and resuspended in 0.3 mL TBS. The cells treated with the disulfide-linked B38-SPP-[3H]DM1 were additionally treated with 5 mmol/L N-ethyl maleimide at room temperature for 30 minutes to alkylate thiol groups. The cell suspensions were assayed for maytansinoid metabolites by HPLC and liquid scintillation counting following acetone extraction as previously described (25).

Live cell imaging and analysis of microtubule dynamic instability

Analysis of microtubule dynamic instability was done as described previously (33, 35), with minor modifications. MCF7 cells were seeded (6 × 10^4/2 mL) on coverslips coated with poly-L-lysine, laminin, and fibronectin in six-well plates. Cells were incubated for 24 hours in culture medium with 10% FBS and then for 24 hours in culture medium with 2% FBS to induce flattening, after which maytansinoid was added at the desired concentration. To control for potential rapid loss of drug from cells upon transfer to the imaging medium (cell culture medium lacking sodium bicarbonate and phenol red, but buffered upon transfer to the imaging medium (cell culture medium with 2% FBS) to induce flattening, after which maytansinoid was added at the desired concentration. To control for potential rapid loss of drug from cells to induce flattening, after which maytansinoid was added at the desired concentration.

Dynamic instability, the lengths of individual microtubules were marked versus elapsed time as life history plots. Microtubule origin point and the plus end were graphed versus time as growth or pause events. Minimal inhibition occurred at a concentration of 200 pmol/L, and inhibition increased gradually with increasing concentrations, attaining the maximum above 300 nmol/L. S-methyl DM1 (IC_{50} = 330 pmol/L) was slightly more potent than maytansine (IC_{50} = 710 pmol/L). Both AMCs had similar IC_{50} values (5.2 nmol/L for uncleavable B38.1-SPP-DM1 and 11 nmol/L for cleavable B38.1-SP-F-DM1). Thus, their potencies were between 1 and 2 orders of magnitude weaker than the unconjugated maytansinoids. Other studies have reported that the free and conjugated maytansinoids had similar IC_{50} values (32, 37). In the previous studies, the target antigens were expressed at much higher levels on the cells than the levels for the EpCAM antigen on the MCF-7 cells in the current study.

We determined the concentration dependence for G2-M arrest at 24 hours of incubation (Fig. 2B) by flow cytometry of cells fixed and stained with propidium iodide (Materials and Methods). All four agents induced a maximum of 80% accumulation of cells in G2-M compared with only 30% in controls (with no drug). The concentration dependence curves for G2-M arrest paralleled the curves for inhibition of proliferation. Minimal G2-M arrest with both maytansine and S-methyl DM1 occurred at 200 pmol/L, and arrest was maximal at 1 nmol/L with half-maximal arrest occurring at 310 and 340 pmol/L, respectively. Minimal inhibition of G2-M arrest with both conjugates occurred at 500 pmol/L, reaching the maximum at ≥100 nmol/L, with IC_{50} values of 7 nmol/L for ≥0.5 μm were considered growth or shortening events. Changes of <0.5 μm were called pause (attenuation). The time-based catastrophe frequency is the number of catastrophes (transitions from growth or pause to shortening) divided by the total time spent growing and paused. The rescue frequency is the number of rescues (transitions from shortening to growth or pause) divided by the total time spent shortening. Dynamicity is the total length grown and shortened divided by the life span of the microtubules. Results are the means and SEM of at least three independent experiments.

Results

Maytansine, S-methyl DM1, and antibody-maytansinoid conjugates inhibit proliferation and arrest cells at mitosis

We measured the effects of maytansine, S-methyl DM1, and EpCAM-targeting disulfide-linked (B38.1-SPP-DM1) and thioether-linked (B38.1-SPP-DM1) conjugates on proliferation of MCF7 cells over 72 hours (Fig. 2A). Both the unconjugated maytansinoids and the conjugated maytansinoids strongly inhibited cell proliferation in a concentration-dependent manner. The concentration dependence curves for the inhibition of cell proliferation by the unconjugated compounds (maytansine and S-methyl DM1) were sigmoidal in shape. Minimal inhibition occurred at 400 pmol/L maytansine and at 200 pmol/L S-methyl DM1, respectively, and inhibition was maximal at 6 and 3 nmol/L, respectively. For both immunoconjugates, minimal inhibition occurred at a concentration of 200 pmol/L, and inhibition increased gradually with increasing concentrations, attaining the maximum above 300 nmol/L. S-methyl DM1 (IC_{50} = 330 pmol/L) was slightly more potent than maytansine (IC_{50} = 710 pmol/L). Both AMCs had similar IC_{50} values (5.2 nmol/L for uncleavable B38.1-SPP-DM1 and 11 nmol/L for cleavable B38.1-SP-F-DM1). Thus, their potencies were between 1 and 2 orders of magnitude weaker than the unconjugated maytansinoids. Other studies have reported that the free and conjugated maytansinoids had similar IC_{50} values (32, 37). In the previous studies, the target antigens were expressed at much higher levels on the cells than the levels for the EpCAM antigen on the MCF-7 cells in the current study.

We determined the concentration dependence for G2-M arrest at 24 hours of incubation (Fig. 2B) by flow cytometry of cells fixed and stained with propidium iodide (Materials and Methods). All four agents induced a maximum of 80% accumulation of cells in G2-M compared with only 30% in controls (with no drug). The concentration dependence curves for G2-M arrest paralleled the curves for inhibition of proliferation. Minimal G2-M arrest with both maytansine and S-methyl DM1 occurred at 200 pmol/L, and arrest was maximal at 1 nmol/L with half-maximal arrest occurring at 310 and 340 pmol/L, respectively. Minimal inhibition of G2-M arrest with both conjugates occurred at 500 pmol/L, reaching the maximum at ≥100 nmol/L, with IC_{50} values of 7 nmol/L for
Arrest with S-methyl DM1 occurred specifically in mitosis as determined by immunostaining with antibodies against phosphorylated histone H3, a marker for mitotic cells. As shown in Fig. 2C, half-maximal mitotic arrest with S-methyl DM1 (IC$_{50}$ 0.4 nmol/L) occurred at the same concentration as G$_2$-M arrest.

The antibody specificity of the conjugate-induced cell cycle arrest was examined in two ways. Incubation of the cells with 11 nmol/L B38.1-SPP-DM1 in the presence of a 90-fold excess of unconjugated B38.1 antibody (1 μmol/L) induced no cell cycle arrest or inhibition of proliferation (data not shown). In addition, incubation of cells with Ab-SPP-DM1 and Ab-SMCC-DM1 conjugates that do not bind to any antigens on the MCF-7/GFP cells also induced no cell cycle arrest or inhibition of proliferation. These observations indicate that the activity of the B38.1-DM1 conjugates is antigen specific.

**Effects of S-methyl DM1 on microtubule organization**

To assess the effects of S-methyl DM1 on the microtubule network, cells were fixed and stained for microtubules, actin, and chromatin and examined by immunofluorescence microscopy (Materials and Methods). In control cells in the interphase, microtubules formed a fine filamentous network throughout the cell and actin formed a filamentous network at the cell periphery (Fig. 3A, a). After 24-hour incubation with 340 pmol/L S-methyl DM1 (the IC$_{50}$ for mitotic arrest), some interphase cells were slightly rounded, but the microtubules and actin fibers in these cells (Fig. 3A, b) were indistinguishable from microtubules in control interphase cells.

At an S-methyl DM1 concentration of 680 pmol/L (2 × IC$_{50}$), the microtubules in interphase cells were shorter, fewer, and had a patchy distribution; small aggregates of tubulin were also apparent (Fig. 3A, c, arrowheads and arrows, respectively). The actin fiber network was unchanged. At 1.4 nmol/L S-methyl DM1 (4 × IC$_{50}$), no microtubules remained, most cells were rounded, and the actin occupied a narrow region at the cell periphery (Fig. 3A, d).

Mitotic spindle organization was examined in cells that were fixed and stained for microtubules, centrosomes, and chromatin. Control mitotic cells had well-separated centrosomes and well-formed bipolar spindles with only a few astral microtubules at the poles (Fig. 3B, e). All chromosomes in control metaphase spindles had congressed into a compact central metaphase plate.

The maytansinoids induced structural and functional spindle microtubule abnormalities at concentrations that induced little or no detectable change in the microtubule network of interphase cells. S-methyl DM1 at 1 × IC$_{50}$ (340 pmol/L) induced striking abnormalities in mitotic cells (Fig. 3B, f–j). The majority had abnormal spindles classified as type I (Fig. 3B, f) or type II bipolar spindles, using the classification of Jordan et al. (38) and Ngan et al. (39), with more and longer astral microtubules than in spindles in control cells, some uncongressed chromosomes, and

![Figure 2. Concentration dependence for inhibition of proliferation (A), G$_2$-M arrest (B), and mitotic arrest of MCF7 cells by maytansinoids and their antibody conjugates (C). Cells were incubated with maytansine (○), S-methyl DM1 (■), B38.1-SPP-DM1 (□), and B38.1-SMCC-DM1 (●). A, cells were incubated with compound for 72 h, and inhibition of proliferation was measured by sulforhodamine B (Materials and Methods). Maytansine, S-methyl DM1, B38.1-SPP-DM1, and B38.1-SMCC-DM1 inhibited proliferation with IC$_{50}$ values 710 pmol/L, 330 pmol/L, 11 nmol/L, and 5.2 nmol/L, respectively. B, cells were incubated with compounds for 24 h, and the population of G$_2$-M cells was determined by flow cytometry (Materials and Methods). Maytansine, S-methyl DM1, B38.1-SPP-DM1, and B38.1-SMCC-DM1 induced arrest in G$_2$-M with IC$_{50}$ values 310 pmol/L, 340 pmol/L, 10 nmol/L, and 6.8 nmol/L, respectively. C, cells were incubated with S-methyl DM1 for 24 h, and the percentage of cells that stained positively for phosphorylated histone H3 was determined by flow cytometry or counted by microscopy (Materials and Methods). S-methyl DM1 induced mitotic arrest with an IC$_{50}$ of 400 nmol/L. Results are means and SEM of at least three experiments.](https://www.aacrjournals.org/mct/article-pdf/9/10/2704/481267/mct2010-0379cr.pdf)
reduced interpolar distances (data not shown; Fig. 3B, g, h). A few cells had spindles that were normal and bipolar with compact metaphase plates of congressed chromosomes, whereas a few mitotically arrested cells had type III abnormal ball-shaped spindles that were often monopolar, with little, if any, separation of the centrosomes (Fig. 3B, i,j). Chromosomes and star-like aggregates of thick microtubules surrounded the centrosomes. S-methyl DM1 at 2 × mitotic IC₅₀ to 4 × mitotic IC₅₀ (680 pmol/L–1.4 nmol/L) induced predominantly type III spindles and increasing numbers of type IV abnormal spindles. In type IV abnormal spindles (Fig. 3B, k,l), only a few short thick microtubules surrounded unseparated or poorly separated centrosomes. There were frequent small tubulin aggregates and bundles of short microtubules that were not connected to the centrosomes. Interestingly,

Figure 3. Effects of S-methyl DM1 on microtubule organization in interphase and mitosis. A, interphase: MCF7 cells were fixed and stained for α-tubulin (green), actin (red), and DNA (blue). Control cells (a) and cells treated for 24 h with 340 pmol/L (mitotic IC₅₀) S-methyl DM1 (b) show intact microtubule and actin networks with similar overall morphologies. At 680 pmol/L S-methyl DM1 (2× mitotic IC₅₀; c), microtubules were significantly shorter (arrowheads), reduced in number, and showed a patchy distribution. Some tubulin aggregates are visible (arrows). At 1.4 nmol/L S-methyl DM1 (4× mitotic IC₅₀; d), all microtubules were depolymerized and actin formed a narrow band at the cell periphery. Scale bar, 10 µm. B, mitosis: MCF7 cells were incubated for 24 h with medium alone (e) or with 340 pmol/L (1 × mitotic IC₅₀; f–j) or 680 pmol/L S-methyl DM1 (2× mitotic IC₅₀; k, l). Cells were fixed and stained for α-tubulin (green), the centrosome-associated protein pericentrin (red), and DNA (blue). In control mitotic cells (e), spindles were normal with well-separated centrosomes and with the chromosomes congressed to a compact metaphase plate. The majority of cells arrested in mitosis by S-methyl DM1 displayed some abnormalities in metaphase: uncongressed chromosomes (red arrows), poorly defined bipolar spindles or monopolar spindles, an increased number of astral microtubules, and poorly separated centrosomes (white arrows). Based on these morphologic abnormalities, cells were categorized into type I, type II, type III, and type IV spindles (see Results). Scale bar, 5 µm.
Figure 4. Comparison of the cellular accumulation of S-[3H]methyl-DM1 with accumulation of the metabolites of cleavable and uncleavable anti-EpCAM antibody-[3H]-DM1 conjugates. A, time course of uptake of 780 pmol/L [3H]-S-methyl DM1 by MCF7 cells. B, diagram depicting the cellular uptake and processing of the anti-EpCAM antibody–DM1 conjugates, B38.1-SMCC-DM1 and B38.1-SPP-DM1. Both conjugates are internalized by antigen-mediated endocytosis. The endosomes containing the conjugates fuse with lysosomes. The conjugates undergo proteolysis, forming the corresponding lysine-linker-maytansinoids, lysine-SMCC-DM1, and lysine-SPPDM1. The lysine-SPP-DM1 metabolite of the cleavable conjugate is further reduced to yield free DM1, whereas the lysine-SMCC-DM1 metabolite of the uncleavable conjugate resists additional processing.

C, radiochromatograms of the [3H]maytansinoid metabolites of B38.1-SPP-[3H]DM1 and B38.1-SMCC-[3H]DM1. MCF-7 cells were exposed to the anti-EpCAM antibody–[3H]-DM1 conjugates for the indicated times. The homogenates were assayed for [3H]-maytansinoid metabolites by extraction and HPLC. The effluent from the samples was collected in 1 mL fractions, and the radioactivity corresponding to each fraction was determined by liquid scintillation counter. The counts per minute of tritium associated with the fractions were plotted versus the time the fraction was collected. The lowest two panels show that coincubation with 1 μmol/L unconjugated EpCAM antibody strongly inhibited the formation of the metabolites.
contrast to other microtubule-interacting compounds, no multipolar spindles occurred at any S-methyl DM1 concentration. Similar concentration-dependent changes in spindle organization occurred on treatment with free maytansine and the B38.1-DM1 conjugates (data not shown). Interestingly, the variety of abnormal spindles for any given concentration and the range of effects on interphase microtubules were greater with the immunoconjugates than with unconjugated maytansinoids, suggesting that the response varied significantly from cell to cell, perhaps due to variable uptake of the immunoconjugates resulting from variations in antigen density.

**Cellular uptake of S-[³H]methyl-DM1 and metabolism of B38.1-SMCC-[³H]DM1 and B38.1-SPP-[³H]DM1**

We examined the time course for uptake of S-[³H]methyl-DM1 into MCF7 cells. As shown in Fig. 4A, at a concentration of 780 pmol/L, S-[³H]methyl-DM1 was taken up relatively rapidly, attaining an intracellular concentration of ~100 nmol/L at 1 hour and a concentration of 400 nmol/L at 5 hours.

To determine the time course for uptake and metabolism of the B38.1-DM1 conjugates, MCF7 cells were exposed to 10 nmol/L B38.1-SMCC-[³H]DM1 or 10 nmol/L B38.1-SMCC-[³H]-DM1 for 5, 9, or 24 hours. The cells were then analyzed for [³H]maytansinoid metabolites by HPLC and liquid scintillation counting following acetone extraction (Fig. 4C). The observed metabolites had retention times identical to the target cell metabolites identified by liquid chromatography/mass spectrometry for the anti-CanAg conjugates, huC242-SMCC-DM1, and huC242-SMCC-DM1 (26). At 5 and 10 hours, lysine-linkermaytansinoid adducts (DM1-SPP-lysine and DM1-SMCC-lysine) were the primary accumulated metabolites of the two conjugates. Even after a prolonged (24 hours) incubation of the cells with B38.1-SMCC-[³H]-DM1 (Fig. 4C, left column), DM1-SMCC-lysine was the major metabolite. In contrast, the lysine-linker-maytansinoid adduct derived from the cleavable EpCAM-SPP-[³H]-DM1 (Fig. 4C, right column) was accompanied at 10 hours by unconjugated DM1 that resulted from the intracellular reduction of the disulfide bond connecting the crosslinker and DM1. At 24 hours, similar levels of the cellular metabolites for the two conjugates formed as indicated by the areas under the peaks. This suggests that the rates for the initial steps through the lysosomal degradation shown in Fig. 4B are similar for the two conjugates. As shown in the bottom two panels of Fig. 4C, a 100-fold excess of unconjugated EpCAM antibody (1 μmol/L) significantly blocked cellular uptake and catabolism of the conjugates.

**Maytansine and S-methyl DM1 suppress dynamic instability of microtubules in cells at concentrations that arrest mitosis**

We examined the effects of free maytansinoids, S-methyl DM1 and maytansine, at their mitotic IC₅₀ values, on dynamic instability of individual microtubules in MCF7 cells at 5-hour incubation, a time when the intracellular drug concentrations had attained equilibrium (Fig. 3A). Figure 5A shows representative frames from a time-lapse series of control cells and from cells incubated with 340 pmol/L S-methyl DM1, showing the changes in length of individual microtubules over time. The length changes were measured (Materials and Methods), and “life history plots” of the changes of the individual microtubules over time (Fig. 5B) were used to determine the parameters of dynamic instability (Table 1A). In control cells, most of the microtubules were dynamic, undergoing frequent transitions between relatively slow growth and rapid shortening. Plus ends of microtubules in control cells shortened at a rate of 20.0 ± 2.3 μm/min and grew at a rate of 12.9 ± 1.0 μm/min (Table 1A). They underwent catastrophes at a frequency of 2.3 ± 0.3/microtubule/min and transitioned to growth or attenuation from shortening (called rescue) at a frequency of 6.6 ± 0.5/microtubule/min. Their overall dynamicity (the total rate of exchange of tubulin with the microtubule end expressed as microtubule length per time) was 12.0 ± 0.6 μm/min.

In contrast, as shown in Table 1A, nearly half of the microtubules in cells incubated with either maytansine (310 pmol/L) or S-methyl DM1 (340 pmol/L; the mitotic IC₅₀ values of the two drugs) were not dynamic; they did not grow or shorten detectably during the observation time. The dynamic instability of microtubules that retained dynamic behavior was significantly suppressed; they grew and shortened more slowly than microtubules in control cells. Maytansine had a somewhat stronger suppressive effect than S-methyl DM1 (Table 1A). The shortening rates were suppressed by maytansine and S-methyl DM1 by 45% and 22%, respectively, and the growth rates were suppressed by 37% and 28%, respectively. Maytansine and S-methyl DM1 suppressed the catastrophe frequency by 61% and 36%, respectively, and enhanced the rescue frequency by 19% and 68%, respectively. Dynamicity was suppressed 65% by maytansine and 58% by S-methyl DM1. The magnitude of suppression increased when the concentration of maytansine or S-methyl DM1 was increased from 1 × IC₅₀ to 2 × IC₅₀ (data not shown).

**Antibody-maytansinoid (B38.1-DM1) conjugates suppress dynamic instability in parallel with intracellular metabolite formation**

To determine whether the conjugate metabolites play a significant role in the antiproliferative and antimitotic mechanisms of the antibody-maytansinoid conjugates, we examined the relationship between metabolite formation and suppression of dynamic instability in the cells. Cells were incubated with 10 nmol/L B38.1-SMCC-DM1 or B38.1-SPP-DM1 for 5, 10, and 24 hours. This concentration approximates the antimitotic IC₅₀ values of the immunoconjugates (7 nmol/L for the uncleavable B38.1-SMCC-DM1 and 10 nmol/L for the cleavable B38.1-SPP-DM1;
Figure 5. Dynamic instability of microtubules in MCF7 cells incubated with maytansine, S-methyl DM1, B38.1-SMCC-DM1, and B38.1-SPP-DM1. Cells were incubated for 5 h with 310 pmol/L maytansine, 340 pmol/L S-methyl DM1, 10.5 nmol/L B38.1-SPP-DM1, and 6.8 nmol/L B38.1-SMCC-DM1 (1 × IC₅₀ concentrations of the corresponding compounds) or medium alone. A, time-lapse images of individual microtubules in the lamellar periphery of cells were recorded by epifluorescence microscopy. Microtubule ends (▴) were tracked over time to produce life history plots. B, life history plots of length of individual microtubules. In all cells treated with maytansinoids, the dynamic instability of individual microtubules was visibly suppressed. Over the 24-h time course of incubation with B38.1-SMCC-DM1 (C) and B38.1-SPP-DM1 (D), suppression of microtubule dynamicity (left axes) increased similarly with the increase in the intracellular concentration of the metabolite of the B38.1-DM1 conjugates as determined by the AUC (area under the curve; right axes) as shown in Fig. 4C.
Table 1. Suppression of MT dynamic instability in MCF7 cells incubated with maytansine, S-methyl DM1, B38.1-SMCC-DM1, and B38.1-SPP-DM1

A. Suppression of MT dynamic instability in MCF7 cells by maytansine and S-methyl DM1 after 5-h incubation with cell cycle 1 × IC₅₀ concentrations

<table>
<thead>
<tr>
<th>MT dynamic instability parameters</th>
<th>Control</th>
<th>S-methyl DM1 (340 pmol/L)</th>
<th>% change</th>
<th>Maytansine (510 pmol/L)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth rate, μm/min</td>
<td>12.9 ± 1.0</td>
<td>9.9 ± 1.2**</td>
<td>−22</td>
<td>6.9 ± 0.5**</td>
<td>−45</td>
</tr>
<tr>
<td>Shortening rate, μm/min</td>
<td>20.0 ± 2.3</td>
<td>14.3 ± 1.6**</td>
<td>−28</td>
<td>12.5 ± 1.3**</td>
<td>−37</td>
</tr>
<tr>
<td>% Time spent growing</td>
<td>51</td>
<td>27</td>
<td>−47</td>
<td>30</td>
<td>−41</td>
</tr>
<tr>
<td>% Time spent shortening</td>
<td>26</td>
<td>14</td>
<td>−45</td>
<td>11</td>
<td>−58</td>
</tr>
<tr>
<td>% Time spent attenuated</td>
<td>23</td>
<td>59</td>
<td>157</td>
<td>59</td>
<td>158</td>
</tr>
<tr>
<td>Catastrophe frequency, no./MT/min</td>
<td>2.5 ± 0.3</td>
<td>1.6 ± 0.2*</td>
<td>−36</td>
<td>1.0 ± 0.1**</td>
<td>−61</td>
</tr>
<tr>
<td>Rescue frequency, no./MT/min</td>
<td>6.6 ± 0.5</td>
<td>11.0 ± 0.7**</td>
<td>68</td>
<td>7.8 ± 0.6</td>
<td>19</td>
</tr>
<tr>
<td>Growth distance, no./MT/μm</td>
<td>0.36 ± 0.06</td>
<td>0.77 ± 0.20</td>
<td>113</td>
<td>0.49 ± 0.07</td>
<td>35</td>
</tr>
<tr>
<td>Shortening distance, no./MT/μm</td>
<td>0.35 ± 0.04</td>
<td>1.11 ± 0.11**</td>
<td>213</td>
<td>0.83 ± 0.10**</td>
<td>136</td>
</tr>
<tr>
<td>Dynamicity</td>
<td>12.0 ± 0.6</td>
<td>5.0 ± 0.6**</td>
<td>−58</td>
<td>4.3 ± 0.3**</td>
<td>−65</td>
</tr>
<tr>
<td>Nondynamic MT</td>
<td>5%</td>
<td>45%</td>
<td>48%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. Time dependence for suppression of MT dynamic instability in MCF7 cells by 10 nmol/L B38.1-SMCC-DM1

<table>
<thead>
<tr>
<th>MT dynamic instability parameters</th>
<th>Control</th>
<th>5 h</th>
<th>% Change 10 h</th>
<th>% Change 24 h</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth rate, μm/min</td>
<td>12.9 ± 1.0</td>
<td>11.4 ± 1.2</td>
<td>−10</td>
<td>11.7 ± 1.6</td>
<td>−8</td>
</tr>
<tr>
<td>Shortening rate, μm/min</td>
<td>20.0 ± 2.3</td>
<td>13.8 ± 1.2**</td>
<td>−31</td>
<td>13.7 ± 2.4**</td>
<td>−31</td>
</tr>
<tr>
<td>% Time spent growing</td>
<td>51</td>
<td>43</td>
<td>−16</td>
<td>39</td>
<td>−24</td>
</tr>
<tr>
<td>% Time spent shortening</td>
<td>26</td>
<td>15</td>
<td>−41</td>
<td>9</td>
<td>−65</td>
</tr>
<tr>
<td>% Time spent attenuated</td>
<td>23</td>
<td>42</td>
<td>83</td>
<td>52</td>
<td>130</td>
</tr>
<tr>
<td>Catastrophe frequency, no./MT/min</td>
<td>2.5 ± 0.3</td>
<td>1.3 ± 0.1**</td>
<td>−48</td>
<td>1.1 ± 0.2**</td>
<td>−55</td>
</tr>
<tr>
<td>Rescue frequency, no./MT/min</td>
<td>6.6 ± 0.5</td>
<td>8.1 ± 0.5</td>
<td>23</td>
<td>10.4 ± 1.0**</td>
<td>58</td>
</tr>
<tr>
<td>Growth distance, no./MT/μm</td>
<td>0.36 ± 0.06</td>
<td>0.40 ± 0.06</td>
<td>11</td>
<td>0.39 ± 0.08</td>
<td>7</td>
</tr>
<tr>
<td>Shortening distance, no./MT/μm</td>
<td>0.35 ± 0.04</td>
<td>0.69 ± 0.06**</td>
<td>95</td>
<td>1.03 ± 0.2**</td>
<td>192</td>
</tr>
<tr>
<td>Dynamicity</td>
<td>12.0 ± 0.6</td>
<td>7.5 ± 0.6**</td>
<td>−37</td>
<td>5.9 ± 0.9**</td>
<td>−51</td>
</tr>
<tr>
<td>Nondynamic MT</td>
<td>5%</td>
<td>6%</td>
<td>17%</td>
<td>3%</td>
<td>44%</td>
</tr>
</tbody>
</table>

C. Time dependence for suppression of MT dynamic instability in MCF7 cells by 10 nmol/L B38.1-SPP-DM1

<table>
<thead>
<tr>
<th>MT dynamic instability parameters</th>
<th>Control</th>
<th>5 h</th>
<th>% Change 10 h</th>
<th>% Change 24 h</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth rate, μm/min</td>
<td>12.9 ± 1.0</td>
<td>10.5 ± 0.7**</td>
<td>−17</td>
<td>9.9 ± 0.8**</td>
<td>−22</td>
</tr>
<tr>
<td>Shortening rate, μm/min</td>
<td>20.0 ± 2.3</td>
<td>14.4 ± 1.3**</td>
<td>−28</td>
<td>12.3 ± 1.4**</td>
<td>−38</td>
</tr>
<tr>
<td>% Time spent growing</td>
<td>51</td>
<td>31</td>
<td>−39</td>
<td>26</td>
<td>−50</td>
</tr>
<tr>
<td>% Time spent shortening</td>
<td>26</td>
<td>21</td>
<td>−21</td>
<td>11</td>
<td>−56</td>
</tr>
<tr>
<td>% Time spent attenuated</td>
<td>23</td>
<td>48</td>
<td>111</td>
<td>63</td>
<td>176</td>
</tr>
<tr>
<td>Catastrophe frequency, no./MT/min</td>
<td>2.5 ± 0.3</td>
<td>1.9 ± 0.1*</td>
<td>−25</td>
<td>1.2 ± 0.1**</td>
<td>−51</td>
</tr>
<tr>
<td>Rescue frequency, no./MT/min</td>
<td>6.6 ± 0.5</td>
<td>7.1 ± 0.5</td>
<td>9</td>
<td>9.6 ± 0.7**</td>
<td>46</td>
</tr>
<tr>
<td>Growth distance, no./MT/μm</td>
<td>0.36 ± 0.06</td>
<td>0.66 ± 0.09*</td>
<td>79</td>
<td>0.75 ± 0.10**</td>
<td>104</td>
</tr>
<tr>
<td>Shortening distance, no./MT/μm</td>
<td>0.35 ± 0.04</td>
<td>0.63 ± 0.06**</td>
<td>79</td>
<td>1.08 ± 0.10**</td>
<td>207</td>
</tr>
<tr>
<td>Dynamicity</td>
<td>12.0 ± 0.6</td>
<td>6.49 ± 0.5**</td>
<td>−46</td>
<td>4.2 ± 0.4**</td>
<td>−65</td>
</tr>
<tr>
<td>Nondynamic MT</td>
<td>5%</td>
<td>20%</td>
<td>42%</td>
<td>21%</td>
<td>38%</td>
</tr>
</tbody>
</table>

NOTE: For A, cells were incubated for 5 h with maytansine or S-methyl DM1 at G₂-M arrest 1 × IC₅₀ concentrations (310 and 340 pmol/L, respectively) before time-lapse microscopy. For B38.1-SMCC-DM1 (B) and B38.1-SPP-DM1 (C), cells were incubated with 10 nmol/L of AMC for the indicated periods of time before time-lapse microscopy. Results presented are average values ± SEM as well as the corresponding percentage of change from control. Values with ** are significantly different from control at ≥99% confidence interval, and values with * are significantly different from control at ≥95% confidence interval by Student’s t test. Values for percentage of time spent in growth, shortening, and attenuation were calculated for the entire population of microtubules and, thus, the confidence intervals for these parameters cannot be computed.

Abbreviation: MT, microtubule.
Fig. 2B) and is the same concentration used in the uptake and metabolism study (Fig. 4C). Incubation with either immunoconjugate for 5 hours moderately suppressed microtubule dynamic instability; the suppressive effects increased at 10 and 24 hours (Table 1B and C). Similar to S-methyl DM1 and maytansine, incubation with B38.1-SMCC-DM1 and B38.1-SPP-DM1 for 5 hours reduced growth rates by 10% and 17%, respectively; shortening rates by 31% and 28%, respectively; and catastrophe frequencies by 48% and 25%, respectively. As shown in Fig. 5C and Table 1B, the suppressive effects on dynamic instability were proportional to the increase in intracellular concentration of the metabolites, attaining 45% and 50% suppression of growth rates, 45% and 61% suppression of shortening rates, and 50% and 75% suppression of the catastrophe frequency for the two immunoconjugates, respectively, at 24-hour incubation. The overall dynamicity at 5 hours was suppressed by 37% and 46% by B38.1-SMCC-DM1 and B38.1-SPP-DM1, respectively, and increased to 75% and 82%, respectively, at 24 hours. The time dependence for inhibition of dynamicity compared with the appearance of the metabolites is shown in Fig. 5. Thus, the cleavable and uncleavable B38.1-DM1 conjugates both disrupt the microtubule dynamic instability in concert with the cellular accumulation of their metabolites. As a control, we added a 100-fold excess of unconjugated B38.1 antibody (1 μmol/L) simultaneously with the conjugates. This completely prevented suppression of microtubule dynamic instability (data not shown), indicating that antibody-mediated uptake of the B38-DM1 conjugates is required to suppress dynamic instability.

Discussion

We found that maytansine, S-methyl DM1, and the anti-EpCAM antibody-maytansinoid conjugates B38.1-SPP-DM1 and B38.1-SMCC-DM1 all inhibited the proliferation of MCF7 cells at subnanomolar or nanomolar concentrations in concert with mitotic arrest and suppression of microtubule dynamic instability. Internalization and metabolism of the conjugates led to continued potent suppression of dynamic instability, indicating that the metabolites and the free unconjugated maytansinoids exert their potent antimitotic effects through a common mechanism involving suppression of microtubule dynamic instability.

Proliferation

We found that maytansine, S-methyl DM1, and the anti-EpCAM conjugates B38.1-SPP-DM1 and B38.1-SMCC-DM1 all inhibited proliferation of MCF7 cells with IC50 values of 710 pmol/L for maytansine, 330 pmol/L for S-methyl DM1, 5.2 nmol/L for B38.1-SPP-DM1, and 11 nmol/L for B38.1-SMCC-DM1. The differences in potency between the conjugates and the free maytansinoids may be attributed to the relatively low expression of the EpCAM antigen on the MCF7 cells. Indeed, the B38.1-SMCC-DM1 conjugate was shown to be much more cytotoxic toward other carcinoma cells than is reported here with MCF7 cells, presumably due to the higher levels of the EpCAM antigen on the other cells (40). Also, in a related study, the cytotoxic potencies of CanAg-targeting antibody maytansinoid conjugates toward cell lines with high levels of the target antigen were found to be similar to the potencies of the free maytansine and S-methyl DM1 (26, 32). We found that the concentration-response curves for the free maytansinoids were steep and S-shaped, whereas the response curves for both conjugates were more linear and increased relatively slowly. This difference in response most likely results from the different mechanisms of cellular uptake for free and conjugated maytansinoids and from the relatively low expression level of the EpCAM antigen on the MCF-7 cells compared with the expression of human epidermal growth factor receptor 2 in previous studies with the trastuzumab-DM1 conjugate (32, 37).

Inhibition of proliferation occur in concert with mitotic arrest

G2-M arrest was induced half-maximally for each compound at a concentration that was similar to the concentration that inhibited proliferation by 50% (half-maximal G2-M arrest at 310 pmol/L maytansine, 340 pmol/L S-methyl DM1, 6.8 nmol/L B38.1-SMCC-DM1, and 10.5 nmol/L B38.1-SPP-DM1). Staining of cells by 4′,6-diamidino-2-phenylindole and phosphohistone-H3 antibody indicated that mitotic arrest occurred predominantly in prometaphase/metaphase of mitosis and that the drugs induced significant drug concentration–dependent abnormalities in the arrested spindles. Thus, inhibition of proliferation occurred by mitotic arrest. Interphase microtubule arrays were normal except at high drug concentrations (2–4 × IC50) at which microtubules were depolymerized and some tubulin accumulations or aggregates were formed.

The maytansinoid-induced spindle abnormalities were strikingly similar to those induced by other microtubule-interacting compounds, including Vinca alkaloids, 2-methoxyestradiol, taxanes, podophyllotoxin, nocodazole, sulforaphane, and eribulin (35, 38, 39, 41). The abnormalities included a concentration-dependent increase in the number of un congressed chromosomes, an increase in the number of astral microtubules, and a shortened pole-to-pole distance. At very high concentrations, spindles were monopolar with a spherical central accumulation of condensed chromosomes and star-shaped aggregates of short, thick microtubules. The failure of congression is likely due to the inability of both kinetochores of sister chromosomes to secure proper attachments to microtubules from opposite poles due to the suppressed dynamic instability of spindle microtubules. The shortened pole-to-pole distance is also likely due to suppression...
of microtubule dynamics and/or to some microtubule depolymerization. Interestingly, we observed no multipolar spindles, suggesting that centrosomal duplication or integrity was unaffected.

**Antibody-maytansinoid conjugates (B38.1-SPP-DM1 and B38.1-SMCC-DM1) are internalized in an antigen-specific manner and metabolized**

Because we found that an excess of unconjugated antibody prevented internalization of both the cleavable and uncleavable B38.1-DM1 conjugates, it is clear that they were internalized by cells in an antigen-specific manner. The lysine adduct produced by metabolism of the uncleavable B38.1-SMCC-DM1 (Lys-SMCC-DM1) was detected in the cells after 5 hours of incubation, and the quantity continued to increase after 10 and 24 hours of incubation. Although the analogous lysine-SPP-DM1 metabolite of the B38.1-SPP-DM1 conjugate was observed in cells at 5 hours and increased in quantity at 10 hours, it underwent an additional reduction to yield DM1 itself at 24 hours. The appearance of the Lys-SPP-DM1 metabolite before DM1 indicates that lysosomal degradation of the antibody component preceded reduction of the disulfide bond in the chemical linker to produce DM1. These findings are in concert with previous studies on metabolism of cleavable and uncleavable antibody-maytansinoid conjugates (25).

**Maytansinoids suppress dynamic instability similarly in cells and with purified microtubules in vitro**

The characteristics of maytansinoid-induced suppression of dynamic instability in cells are similar in most respects, qualitatively and quantitatively, to results on the suppressive effects of maytansine and S-methyl DM1 on dynamic instability of purified bovine brain microtubules reported in the accompanying article (30). For example, 340 pmol/L S-methyl DM1 added to MCF7 cells suppressed microtubule growth rates by 22%, compared with 24% suppression by 100 nmol/L S-methyl DM1 with purified microtubules. Similarly, shortening rates were suppressed by 28% and 67%, respectively; the catastrophe frequency was suppressed by 36% and 90%, respectively; and overall dynamicity was suppressed by 58% and 84%, respectively.

Comparing the intracellular concentration of S-methyl DM1 with the concentration that was added to the medium indicated that the intracellular concentration increased about 500-fold. (Addition of 780 pmol/L S-methyl DM1 to the cells resulted in an intracellular concentration of 400 nmol/L; Fig. 4A.) A similar cellular uptake phenomenon is frequently observed with other microtubule-targeted drugs (42, 43). From these data, we estimate that the addition of 340 pmol/L S-methyl DM1 to the cells would have resulted in an intracellular concentration of ~80 nmol/L S-methyl DM1, similar to the concentration of 100 nmol/L that was used in vitro with purified microtubules. Thus, the effective concentrations in cells and in vitro with purified microtubules are similar.

The only significant difference between the dynamics results in cells and in vitro was that the rescue frequency was affected in opposite ways in the two environments. It was reduced by 44% by 100 nmol/L S-methyl DM1 with purified microtubules, whereas it was increased 68% by 340 pmol/L S-methyl DM1 in cells. A possible explanation for this difference is that microtubule tips that are not capped by GTP-tubulin but instead have exposed GDP-tubulin at their tips are thought to have an unstable conformation that can undergo rapid microtubule depolymerization. Rescue of such a rapid shortening or depolymerization event may occur at microtubule regions where tubulin with bound GTP or with a GTP-like conformation exist in the body of the microtubule (44). It is conceivable that in the complex milieu of the cell, maytansine, or S-methyl DM1 interacts with some of the many proteins that associate with microtubules (microtubule-associated proteins, protein motors, etc.) and thereby prevents some regions of the microtubule from completing GTP hydrolysis or from attaining the unstable GDP-associated conformation, thus increasing the rescue frequency; however, in vitro with purified microtubules and no microtubule-associated proteins, such stabilized regions may not exist.

In all respects except for the opposite effects on rescue frequency, the in vitro results are similar to the results reported for cells (Table 1), indicating that the maytansinoid mechanisms in the complex milieu of the cell are similar to those in vitro. Thus, both in cells and in vitro, at low concentrations (those that induce mitotic arrest), it seems that maytansinoids stabilize microtubule dynamics by suppressing microtubule growth and shortening and catastrophe by binding with high affinity to a few sites at microtubule ends (30). At higher concentrations, the maytansinoids depolymerize microtubules both in vitro and in cells.

**Metabolites suppress dynamic instability similarly to the unconjugated compound, in concert with their cellular accumulation**

Like the free maytansinoids, the cleavable and uncleavable B38.1-DM1 conjugates and their metabolites inhibited cell proliferation and arrested cells in mitosis by suppressing microtubule dynamic instability. Dynamic instability was significantly inhibited by the low levels of metabolites produced at 5 hours of incubation, and inhibition increased significantly after 10 and 24 hours incubation (Table 1; Fig. 5). At the concentrations that induced half-maximal G2-M arrest, the conjugates suppressed or enhanced the same microtubule dynamic parameters to similar degrees and in similar directions as free S-methyl DM1 and maytansine. Both growth and shortening rates, the catastrophe frequency, and dynamicity were suppressed by all four maytansinoids, and the rescue frequency was enhanced. As shown in Fig. 5C
and D, the time dependence for increased effects on microtubule dynamicity paralleled the increase in intracellular metabolite concentration arising from metabolism of B38.1-SMCC-DM1. For the cleavable B38.1-SPP-DM1, the time dependence for the sum of the concentrations of the two metabolites approximately paralleled the time dependence for increase in suppression of microtubule dynamicity. Thus, the results indicate that the metabolites and the free unconjugated maytansinoids have similar mechanisms of action, exerting their antiproliferative effects by inhibiting mitosis through suppression of microtubule dynamic instability.

References


Molecular Cancer Therapeutics

Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Emin Oroudjev, Manu Lopus, Leslie Wilson, et al.

Mol Cancer Ther 2010;9:2700-2713.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/9/10/2700

Cited articles
This article cites 40 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/9/10/2700.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/9/10/2700.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.